Sameer Bansilal MD, MS (@sameerbansilal) 's Twitter Profile
Sameer Bansilal MD, MS

@sameerbansilal

Heart doctor with common sense. I tweet my own horn. Trialist @MountSinaiHeart @TIMIStudygroup VP-@Alnylam Ex-VP@Bayer Bronx VAMC (WOC) Report to @amrita_gupte

ID: 41590148

linkhttps://www.doximity.com/pub/sameer-bansilal-md calendar_today21-05-2009 13:56:05

3,3K Tweet

1,1K Followers

734 Following

Narendra Modi (@narendramodi) 's Twitter Profile Photo

Herath Poshte! This festival is closely associated with the vibrant culture of our Kashmiri Pandit sisters and brothers. On this auspicious occasion, I wish for harmony, good health and prosperity for everyone. May it also fulfil dreams, create new opportunities and bring

Alnylam Pharmaceuticals (@alnylam) 's Twitter Profile Photo

We are thrilled to share that the U.S. FDA has approved our supplemental New Drug Application (sNDA) for AMVUTTRA® (vutrisiran), making it available as a treatment option for a new group of patients. Read the press release: bit.ly/4kHlC1M #RNAi #RNAiTherapeutics

Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

Vutrisiran for transthyrtin amyloid cardiomyopathy is now FDA approved to reduce mortality, CVH, and urgent HF visits Label alnylam.com/sites/default/… #CardioTwitter

Vutrisiran for transthyrtin amyloid cardiomyopathy is now FDA approved to reduce mortality, CVH, and urgent HF visits

Label 
alnylam.com/sites/default/…

#CardioTwitter
Ronald Witteles (@ron_witteles) 's Twitter Profile Photo

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a
Mounir Basalus (Ⲃⲁⲥⲓⲗⲓⲟⲥ) (@basalus) 's Twitter Profile Photo

1/7 Vutrisiran (AMVUTTRA) is an RNAi therapeutic indicated for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). A game-changer for a devastating progressive disease. [1]

1/7
Vutrisiran (AMVUTTRA) is an RNAi therapeutic indicated for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). A game-changer for a devastating progressive disease. [1]
Novi Yanti Sari (@slumberbell) 's Twitter Profile Photo

HELIOS-B: #Vutrisiran reduces all-cause mortality, presented by Marianna Fontana 📍 Significant reduction in all-cause & #CVdeath ☠️ over 42 months vs placebo 📍 Lower rates of #CVevents and #HF hospitalisations 🏥 over 36 months vs placebo #ATTR #cardiacamyloidosis

HELIOS-B: #Vutrisiran reduces all-cause mortality, presented by <a href="/MariannaFonta11/">Marianna Fontana</a>

📍 Significant reduction in all-cause &amp; #CVdeath ☠️ over 42 months vs placebo
📍 Lower rates of #CVevents and #HF hospitalisations 🏥 over 36 months vs placebo

#ATTR #cardiacamyloidosis
Sameer Bansilal MD, MS (@sameerbansilal) 's Twitter Profile Photo

investors.alnylam.com/press-release?… – Additional 42-Month Data Reinforce Vutrisiran’s Impact on the Risk of All-Cause Mortality and CV Mortality – Substantial Benefit Across a Range of CV Events, Notably Reducing Urgent Heart Failure Visits by 46%

Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B vutrisiran reliably reduced the risk of ACM, CV mortality, CV hospitalizations, HF hospitalizations, and urgent HF visit #HeartFailure2025 jacc.org/doi/10.1016/j.…

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B

vutrisiran reliably reduced the risk of ACM, CV mortality, CV hospitalizations, HF hospitalizations, and urgent HF visit

#HeartFailure2025 

jacc.org/doi/10.1016/j.…
JACC Journals (@jaccjournals) 's Twitter Profile Photo

📉 Earlier is better: Vutrisiran works across ATTR-CM stages, but the biggest survival gains come in early disease. Time is myocardium. jacc.org/doi/10.1016/j.… #JACC #HELIOSB #ATTRCM #Vutrisiran #Amyloidosis mathew.maurer Ronald Witteles

📉 Earlier is better: Vutrisiran works across ATTR-CM stages, but the biggest survival gains come in early disease. Time is myocardium. jacc.org/doi/10.1016/j.…

#JACC #HELIOSB #ATTRCM #Vutrisiran #Amyloidosis <a href="/MathewMaurer/">mathew.maurer</a> <a href="/Ron_Witteles/">Ronald Witteles</a>
Rajiv Agarwal MD, MS (@agarwalrajivmd) 's Twitter Profile Photo

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.